Crowdonomics
All companies
Vymedic logo

Vymedic

Operating

Vymedic Inc.

Healthcare · Founded 2020

Visit website

Scientifically proven broad-spectrum antiviral beats industry-leading treatments in the suppression of flu, colds and common viruses.

Post-money valuation ⓘ
$20.2M
As of Mar 2021 · from Vymedic Stock 1 · pre-money + amount raised, not a traded price
Total raised
$202,470
Across 1 round since 2020
Latest share price
$5.00
Vymedic Stock 1 offering price

Financials

FY2018–FY2021 · from SEC filings · hover any figure for its source
$0
−$46K
2018
$0
−$47K
2019
$0
−$208K
2020
$10K
−$296K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2021
Income statement
Revenue
$0
$0
$0
$10,349
Cost of goods sold
$0
$0
$0
$3,653
Gross margin
—
—
—
65%
Net income
-$45,688
-$46,788
-$208,331
-$295,575
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$3,105
$2,032
$6,411
$247,729
Accounts receivable
$0
$0
$0
$1,136
Total assets
$3,105
$2,032
$46,286
$752,595
Short-term debt
$0
$0
$0
$0
Long-term debt
$0
$0
$129,915
$1,103,070
Total liabilities
$0
$0
$129,915
$1,103,070
Other
Headcount
—
2
—
2

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$20.2M
post-money
Vymedic Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Vymedic Stock 1ClosedReg CF · Common Equity · via Netcapital
Raised $202.5K / $1.1MPost-money $20.2M

Team

5 people
Cynthia Winning
Principal Executive Officer
David Bartlett
Board Member
Gerald Mills
Board Member
Lee Peterson
Principal Financial Officer
Stephen Lehman
Board Member

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Possibly delinquent

Filed 1 of 6 annual reports (FY2020–FY2025)

Missing: 2020, 2022, 2023, 2024, 2025

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 13 filings on EDGAR
  • Form C-ARApr 29, 20220001669191-22-000460
    EDGAR
  • Form C-UApr 16, 20210001669191-21-000392
    EDGAR
  • Form DMar 4, 20210001567619-21-005640
    EDGAR
  • Form C/AJan 22, 20210001669191-21-000073
    EDGAR
  • Form C/AJan 20, 20210001669191-21-000053
    EDGAR
  • Form C/ADec 23, 20200001669191-20-000853
    EDGAR
  • Form C/ANov 23, 20200001669191-20-000709
    EDGAR
  • Form C/ANov 19, 20200001669191-20-000698
    EDGAR
Source: ManualCIK 0001824940Share price $5.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.